SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

11/4/24 11:20:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PHAT alert in real time by email

SC 13G 1 PHAT102024.txt 13G PHAT 10312024 Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* October 31, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of Issuer: Phantom Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 71722W107 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 71722W107 1. Name of Reporting Person: Jennison Associates LLC S.S. or I.R.S. Identification No. of Above Person: IRS Identification #52-2069785 (formerly 13-2631108) 2. Check the Appropriate Box if a Member of a Group: Not Applicable 3. SEC Use Only 4. Citizenship or Place of Organization: Delaware Number of Shares Beneficially Owned By Each Reporting Person With: 5. Sole Voting Power: 6,993,422 shares 6. Shared Voting Power: 0 shares 7. Sole Dispositive Power: 0 shares 8. Shared Dispositive Power: 6,993,422 shares 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 6,993,422 shares 10. Check Box if the Aggregate Amount in Row 9 Excludes Certain Shares: ( ) 11. Percent of Class Represented by Amount in Row 9: 10.4% 12. Type of Reporting Person*: IA Item 1(a) Name of Issuer: Phantom Pharmaceuticals Inc Item 1(b) Address of Issuer's Principal Executive Offices: 100 Campus Drive, Suite 102 Florham Park, NJ 07932 Item 2(a) Name of Person Filing: Jennison Associates LLC Item 2(b) Address of Principal Business Office or Residence: 466 Lexington Avenue New York, NY 10017 Item 2(c) Citizenship: Delaware Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 71722W107 Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), or (c) check whether the person filing is a: (a) ( ) Broker or Dealer registered under Section 15 of the Act (b) ( ) Bank as defined in Section 3(a) (6) of the Act (c) ( ) Insurance Company as defined in Section 3(a) (19) of the Act (d) ( ) Investment Company registered under Section 8 of the Investment Company Act (e) (X) Investment Adviser in accordance with Section 240.13d-1(b) (1) (ii) (E) (f) ( ) Employee Benefit Plan, Pension Fund which is subject to the provision of the Employee Retirement Income Security Act of 1974 or Endowment Fund in accordance with Section 240.13d-1(b) (ii) (F) (g) ( ) Parent Holding Company or control person, in accordance with Section 240.13(b) (ii) (G) (h) ( ) A savings association as defined by Section 3(b) of the Federal Deposit Insurance Act (i)( ) A church plan that is excluded from the definition of an investment company under Section 3(c) (4) of the Investment Company Act of 1940. (j)( ) Group, in accordance with Section 240.13d-1(b) (1) (ii) (J). If this statement is filed pursuant to Section 240.13d-1(c), check this box. ( ) Item 4 Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 6,993,422 shares (b) Percent of Class: 10.4% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 6,993,422 shares (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 6,993,422 shares Jennison Associates LLC ("Jennison") furnishes investment advice to several investment companies, insurance separate accounts, and institutional clients ("Managed Portfolios"). As a result of its role as investment adviser of the Managed Portfolios, Jennison may be deemed to be the beneficial owner of the shares of the Issuer's Common Stock held by such Managed Portfolios. Prudential Financial, Inc. ("Prudential") indirectly owns 100% of equity interests of Jennison. As a result, Prudential may be deemed to have the power to exercise or to direct the exercise of such voting and/or dispositive power that Jennison may have with respect to the Issuer's Common Stock held by the Managed Portfolios. Jennison does not file jointly with Prudential, as such, shares of the Issuer's Common Stock reported on Jennison's 13G may be included in the shares reported on the 13G filed by Prudential. These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Jennison is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the securities, check the following ( ). Item 6 Ownership of More than Five Percent on Behalf of Another Person: Our clients have the right to receive or the power to direct the receipt of dividends or the profits from the sale of such securities. No one client owns more than 5% of such security class. Item 7 Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company: Not Applicable Item 8 Identification and Classification of Members of the Group: Not Applicable Item 9 Notice of Dissolution of Group: Not Applicable Item 10 Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are in held the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the correct information set forth in this statement is true, complete and correct. September 5, 2024 /s/ Beata Markowicz Beata Markowicz Vice President

Get the next $PHAT alert in real time by email

Date

Price Target

Rating

Analyst

5/3/2024

$24.00

Buy

Stifel

1/5/2024

$23.00 → $26.00

Buy

Needham

8/9/2023

$28.00

Buy

H.C. Wainwright

5/11/2023

In-line → Outperform

Evercore ISI

3/13/2023

$21.00

Buy

Craig Hallum

10/21/2022

$16.00

Buy

Jefferies

5/6/2022

Outperform → In-line

Evercore ISI

SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $PHAT

$PHAT SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.

SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.

SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

$PHAT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stifel initiated coverage on Phathom Pharmaceuticals with a new price target

Needham reiterated coverage on Phathom Pharmaceuticals with a new price target

H.C. Wainwright initiated coverage on Phathom Pharmaceuticals with a new price target

$PHAT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Parikh Asit bought $58,580 worth of shares (7,500 units at $7.81), increasing direct ownership by 16% to 55,000 units (SEC Form 4)

$PHAT Financials

Live finance-specific insights

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

$PHAT Market Insights

Live Market Insights

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

$PHAT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$PHAT Large Ownership Changes

This live feed shows all institutional transactions in real time.

$PHAT Leadership Updates

Live Leadership Updates

$PHAT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc. (Amendment)

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

Chief Operating Officer Nabulsi Azmi sold $127,760 worth of shares (10,901 units at $11.72), decreasing direct ownership by 4% to 240,421 units (SEC Form 4)

CFO and CBO Henderson Molly sold $50,689 worth of shares (4,325 units at $11.72), decreasing direct ownership by 4% to 99,447 units (SEC Form 4)

President and Chief Executive Curran Terrie sold $396,699 worth of shares (33,848 units at $11.72), decreasing direct ownership by 8% to 377,734 units (SEC Form 4)

$PHAT Press Releases

Fastest customizable press release news feed in the world

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Recent Analyst Ratings for
$PHAT

$PHAT
SEC Filings

$PHAT
Analyst Ratings

$PHAT
Insider Purchases

$PHAT
Financials

$PHAT
Market Insights

$PHAT
FDA approvals

$PHAT
Large Ownership Changes

$PHAT
Leadership Updates

$PHAT
Insider Trading

$PHAT
Press Releases